Ensho Therapeutics revealed that it has secured a portfolio of oral α4β7 integrin inhibitors under an exclusive global license agreement with EA Pharma Co., Ltd., a division of Eisai Co., Ltd.

Elevation Oncology Unveils New Strategy for EO-3021 in Gastric and Gastroesophageal Junction Cancer Patients.

Bicara Therapeutics Announces New Interim Phase 1/1b Data for Ficerafusp Alfa (BCA101) in First-Line HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).

Meitheal Pharmaceuticals has obtained exclusive U.S. commercial rights for YUSIMRY, a biosimilar to Humira.

CASI Pharmaceuticals Plans IND Submission for CID-103 in Antibody-Mediated Rejection and Receives Non-Binding Offer to Acquire Its China Operations.

The U.S. FDA has granted approval to EPKINLY® (epcoritamab-bysp) for individuals with relapse or refractory (R/R) follicular lymphoma (FL).

Lyell Immunopharma Announces Phase 1 Results for ROR1-targeted CAR-T Candidate, LYL797, Showing Dose-dependent Efficacy Enhanced by Anti-exhaustion Technology.

Simcere Zaiming, announced that their new anti-EGFR antibody treatment, Enlituo®, has been officially approved for sale by the China National Medical Administration.

HUADONG MEDICINE Reports Encouraging Phase I Outcomes for New Oral GLP-1 Receptor Agonist HDM1002.

Star Therapeutics Unveils Clinical Findings on VGA039, an Injectable Therapy for Von Willebrand Disease (VWD).

Arrowhead Pharmaceuticals to Progress RNAi Therapy Plozasiran into Phase 3 CAPITAN Trial for Cardiovascular Results.

Werewolf Therapeutics Presents Early Safety and Effectiveness Results from Phase 1 Study of WTX-330 in Patients with Advanced Solid Tumors or Non-Hodgkin Lymphoma.